Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

(2019) Francesco Panza et al.   Nature Reviews Neurology

Methylene blue protects dopaminergic neurons against MPTP-induced neurotoxicity by upregulating brain-derived neurotrophic factor

(2018) Sunil Bhurtel et al.   Annals of the New York Academy of Sciences

Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development

(2018) Claude M. Wischik et al.   JOURNAL OF ALZHEIMERS DISEASE

Methylene Blue Ameliorates Olfactory Dysfunction and Motor Deficits in a Chronic MPTP/Probenecid Mouse Model of Parkinson’s Disease

(2018) K.C. Biju et al.   NEUROSCIENCE

Profiling attention and cognition enhancing drugs in a rat touchscreen-based continuous performance test

(2018) Zhiyong Ding et al.   PSYCHOPHARMACOLOGY

France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer’s Disease

(2018) Pierre Krolak-Salmon et al.   JOURNAL OF ALZHEIMERS DISEASE

Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT)

(2018) Youssra K. Al-Hilaly et al.   JOURNAL OF MOLECULAR BIOLOGY

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

(2017) Gordon K. Wilcock et al.   JOURNAL OF ALZHEIMERS DISEASE

Cryo-EM structures of tau filaments from Alzheimer’s disease

(2017) Anthony W. P. Fitzpatrick et al.   NATURE

Daily consumption of methylene blue reduces attentional deficits and dopamine reduction in a 6-OHDA model of Parkinson’s disease

(2017) Elizabeth S. Smith et al.   NEUROSCIENCE

Tau: From research to clinical development

(2016) David M. Holtzman et al.   Alzheimers & Dementia

Cholinergic genetics of visual attention: Human and mouse choline transporter capacity variants influence distractibility

(2016) Martin Sarter et al.   JOURNAL OF PHYSIOLOGY-PARIS

Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study

(2016) Daniela Koller et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

Defeating Alzheimer's disease and other dementias: a priority for European science and society

(2016) Bengt Winblad et al.   LANCET NEUROLOGY

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models

(2015) Valeria Melis et al.   BEHAVIOURAL PHARMACOLOGY

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease

(2015) Charles R. Harrington et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Methylene blue exerts a neuroprotective effect against traumatic brain injury by promoting autophagy and inhibiting microglial activation

(2015) MINGFEI ZHAO et al.   Molecular Medicine Reports

Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity

(2014) Cliona Stack et al.   HUMAN MOLECULAR GENETICS

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

(2013) Parminder Raina et al.   ANNALS OF INTERNAL MEDICINE

Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study

(2013) Carlos Martinez et al.   BMJ Open

Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo

(2012) Erin E. Congdon et al.   Autophagy

Mitochondrial pharmacology: Electron transport chain bypass as strategies to treat mitochondrial dysfunction

(2012) Hani Atamna et al.   BIOFACTORS

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Involvement of the cholinergic system in conditioning and perceptual memory

(2011) Lianne Robinson et al.   BEHAVIOURAL BRAIN RESEARCH

“Lest we forget you — methylene blue …”

(2011) R. Heiner Schirmer et al.   NEUROBIOLOGY OF AGING

Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator

(2011) Francois Gastambide et al.   NEUROPSYCHOPHARMACOLOGY

The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies

(2010) Inge Klinkenberg et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Methylene blue and Alzheimer's disease

(2009) Murat Oz et al.   BIOCHEMICAL PHARMACOLOGY

Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry

(2008) Jürgen Burhenne et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways

(2007) Hani Atamna et al.   FASEB JOURNAL